

AMENDMENTS TO THE TITLE

Replace the title with:

UTILIZATION OF VINPOCETINE TO ~~AVOID COMPLICATIONS IN PARTICULAR~~
~~THOSE ASSOCIATED TO HEARING WHICH OCCUR~~ TREAT OR PREVENT
HEARING LOSS ASSOCIATED WITH EPILEPSY, ~~AND TREATMENT THEREOF~~

AMENDMENTS TO THE SPECIFICATION

Replace paragraph [0033] with:

[0033] The next table shows that vinpocetine inhibits the reduction in P4 wave peak amplitude induced by PTZ. In the control animals (pre-injected with vehicle) the amplitude of the P4 wave of the ABR induced by a stimulus of 100 dB at two tone frequencies (8 and 4 kHz) is progressively reduced by PTZ (left columns), whereas in the animals pre-injected with vinpocetine the reduction produced induced by PTZ in P4 amplitude is not observed (right columns). The values shown on the table are the mean \pm standard errors of the P4 wave amplitudes in μ V obtained from 8 animals before and at the indicated times after the injection of the convulsing agent (PTZ).

	8 kHz	8 kHz
	PTZ	Vinpocetine & PTZ
<i>Before</i>	2.88 ± 0.1	2.69 ± 0.1
<i>10 min</i>	$2.07 \pm 0.4 *$	2.56 ± 0.1
<i>20 min</i>	$1.99 \pm 0.3 *$	2.71 ± 0.2
<i>30 min</i>	$1.92 \pm 0.3 *$	2.55 ± 0.2
<i>50 min</i>	$1.51 \pm 0.5 *$	2.56 ± 0.1

	4 kHz	4 kHz
	PTZ	Vinpocetine & PTZ
<i>Before</i>	3.14 ± 0.1	2.82 ± 0.3
<i>10 min</i>	$1.70 \pm 0.5 *$	2.55 ± 0.3
<i>20 min</i>	$2.12 \pm 0.4 *$	2.52 ± 0.2
<i>30 min</i>	$1.84 \pm 0.4 *$	2.55 ± 0.2
<i>50 min</i>	$2.11 \pm 0.3 *$	2.52 ± 0.2

The symbol “*” indicates that a statistically significant difference was observed.

Replace paragraph [0035] with:

[0035] The next table shows that vinpocetine inhibits the hearing loss induced by the convulsing agent, PTZ. The marked increase on the auditory threshold at 4 and 8 kHz tone

frequencies induced by PTZ (left columns) is not produced in the animals pre-injected with vinpocetine before PTZ administration (right columns). The values shown on the table are the mean \pm standard errors of the thresholds in dB obtained in 8 animals.

	PTZ	Vinpocetine & PTZ
8 kHz		
<i>Before</i>	7.0 ± 1.2	6.0 ± 1.0
<i>30 min</i>	17 ± 2.0 *	6.0 ± 1.0
<i>50 min</i>	21 ± 2.4 *	6.0 ± 1.0
4 kHz		
<i>Before</i>	21 ± 1.0	20 ± 1.6
<i>30 min</i>	28 ± 2.0 *	18 ± 1.2
<i>50 min</i>	29 ± 1.0 *	18 ± 1.2

The symbol “*” indicates that a statistically significant difference was observed.

Replace paragraph [0041] with:

[0041] The following table shows that the increased latency of the P4 wave of the ABR induced by the stimulus of 100 dB at 4 and 8 kHz tone frequencies observed at the indicated times after the injection of 4-AP in control animals (left columns), is lost when 4-AP is injected in the vinpocetine pre-treated animals (right columns).

	8 kHz 4-AP	8 kHz Vinpocetine & 4-AP
<i>Before</i>	3.48 ± 0.06	3.48 ± 0.04
<i>30 min</i>	3.51 ± 0.13	3.55 ± 0.07
<i>60 min</i>	3.80 ± 0.10 *	3.45 ± 0.08
<i>80 min</i>	3.80 ± 0.10 *	3.36 ± 0.05
<i>100 min</i>	3.83 ± 0.12 *	3.35 ± 0.07

	4 kHz 4-AP	4 kHz Vinpocetine & 4-AP
<i>Before</i>	3.50 ± 0.02	3.45 ± 0.06
<i>30 min</i>	3.78 ± 0.09 *	3.37 ± 0.06
<i>60 min</i>	3.78 ± 0.09 *	3.54 ± 0.11
<i>80 min</i>	3.78 ± 0.09 *	3.56 ± 0.04
<i>100 min</i>	3.75 ± 0.10 *	3.43 ± 0.09

The symbol “*” indicates that a statistically significant difference was observed.

Replace paragraph [0041] with:

[0042] Vinpocetine inhibits the hearing loss induced by 4-AP. The following table shows that the increase on the auditory threshold induced by 4-AP at 8 and 4 kHz tone frequencies in control animals (left columns) is lost in the vinpocetine treated animals (right columns).

	4-AP	Vinpocetine & 4-AP
<hr/>		
8 kHz		
Before	3.8 ± 1.3	2.5 ± 1.4
30 min	10.0 ± 2.0 *	-1.3 ± 2.4
60 min	23.8 ± 6.3 *	0.0 ± 3.5
4 kHz		
Before	13.8 ± 1.3	13.8 ± 1.3
30 min	20 ± 2.0 *	11.3 ± 1.3
60 min	30 ± 3.5 *	11.3 ± 1.3
<hr/>		

The symbol “*” indicates that a statistically significant difference was observed.